Grainne M O'Kane
Research Subjects
Grainne M O'Kane has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Steven Gallinger
Centre d’oncologie Princess Margaret (O’Kane, Gallinger), Réseau universitaire de santé de Toronto, Toronto, Ont.; Université de l’Alberta (Ladak), Edmonton, Alb
3 shared publicationsFarah Ladak
Centre d’oncologie Princess Margaret (O’Kane, Gallinger), Réseau universitaire de santé de Toronto, Toronto, Ont.; Université de l’Alberta (Ladak), Edmonton, Alb
2 shared publicationsAmy Zhang
PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research
1 shared publicationAnna Dodd
Department of Medial Oncology and Hematology, Princess Margaret Cancer Centre
1 shared publication- Barbara Grunwald
Department of Urology, West German Cancer Center, University Hospital Essen, Essen, Germany
1 shared publication Bernard Lam
Adaptive Oncology, Ontario Institute for Cancer Research
1 shared publication
Latest Publications
- Open Access
- 29 August 2021
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 193 (34) , E1362-E1370
Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique
- 29 August 2021
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 193 (34) , E1362-E1370
Open AccessAvancées dans la prise en charge de l’adénocarcinome canalaire pancréatique
- Open Access
- 7 June 2021
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 193 (23) , E844-E851
Advances in the management of pancreatic ductal adenocarcinoma
- 7 June 2021
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 193 (23) , E844-E851
Open AccessAdvances in the management of pancreatic ductal adenocarcinoma
- Open Access
- 29 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 2065-2078
Interventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review
While adjuvant treatment of colon cancers that penetrate the serosa (T4) have been well-established, neoadjuvant strategies have yet to be formally evaluated. Our objective was to perform a scoping review of eligibility criteria, treatment regimens, and primary outcomes for neoadjuvant approaches to T4 colon cancer. A librarian-led, systematic search of MEDLINE, Embase, Cochrane Library, Web of Science, and CINAHL up to 11 February 2020 was performed. Primary research evaluating neoadjuvant treatment in T4 colon cancer were included. Screening and data abstraction were performed in duplicate; analyses were descriptive or thematic. A total of twenty studies were included, most of which were single-arm, single-center, and retrospective. The primary objectives of the literature to date has been to evaluate treatment feasibility, tumor response, disease-free survival, and overall survival in healthy patients. Conventional XELOX and FOLFOX chemotherapy were the most commonly administered interventions. Rationale for selecting a specific regimen and for treatment eligibility criteria were poorly documented across studies. The current literature on neoadjuvant strategies for T4 colon cancer is overrepresented by single-center, retrospective studies that evaluate treatment feasibility and efficacy in healthy patients. Future studies should prioritize evaluating clear selection criteria and rationale for specific neoadjuvant strategies. Validation of outcomes in multi-center, randomized trials for XELOX and FOLFOX have the most to contribute to the growing evidence for this poorly managed disease.
- 29 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 2065-2078
Open AccessInterventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review
While adjuvant treatment of colon cancers that penetrate the serosa (T4) have been well-established, neoadjuvant strategies have yet to be formally evaluated. Our objective was to perform a scoping review of eligibility criteria, treatment regimens, and primary outcomes for neoadjuvant approaches to T4 colon cancer. A librarian-led, systematic search of MEDLINE, Embase, Cochrane Library, Web of Science, and CINAHL up to 11 February 2020 was performed. Primary research evaluating neoadjuvant treatment in T4 colon cancer were included. Screening and data abstraction were performed in duplicate; analyses were descriptive or thematic. A total of twenty studies were included, most of which were single-arm, single-center, and retrospective. The primary objectives of the literature to date has been to evaluate treatment feasibility, tumor response, disease-free survival, and overall survival in healthy patients. Conventional XELOX and FOLFOX chemotherapy were the most commonly administered interventions. Rationale for selecting a specific regimen and for treatment eligibility criteria were poorly documented across studies. The current literature on neoadjuvant strategies for T4 colon cancer is overrepresented by single-center, retrospective studies that evaluate treatment feasibility and efficacy in healthy patients. Future studies should prioritize evaluating clear selection criteria and rationale for specific neoadjuvant strategies. Validation of outcomes in multi-center, randomized trials for XELOX and FOLFOX have the most to contribute to the growing evidence for this poorly managed disease.
- Top Cited Papers
- 10 March 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (18) , 4901-4910
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Purpose: To determine the impact of basal-like and classical subtypes in advanced PDAC and to explore GATA6 expression as a surrogate biomarker. Experimental design: Within the COMPASS trial patients proceeding to chemotherapy for advanced PDAC undergo tumour biopsy for RNA sequencing. Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) were explored. Results: Between December 2015-May 2019, 195 patients (95%) had enough tissue for RNA sequencing; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% vs. 33% respectively (p=0.02). In patients with basal-like tumours treated with modified FOLFIRINOX (mFFX) (n=22) the progression rate was 60% compared to 15% in classical PDAC (p= 0.0002). Median OS in the intention to treat population (n=195) was 9.3 months for classical vs. 5.9 months for basal-like PDAC (HR 0.47 95% CI 0.32-0.69, p=0.0001). GATA6 expression by RNAseq highly correlated with the classifier (p<0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariable analysis, GATA6 expression was prognostic (p=0.02). In exploratory analyses, basal-like tumours, could be identified by keratin 5, were more hypoxic and enriched for a T cell inflamed gene expression signature. Conclusions :The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression.
- 10 March 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (18) , 4901-4910
Top Cited PapersGATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Purpose: To determine the impact of basal-like and classical subtypes in advanced PDAC and to explore GATA6 expression as a surrogate biomarker. Experimental design: Within the COMPASS trial patients proceeding to chemotherapy for advanced PDAC undergo tumour biopsy for RNA sequencing. Overall response rate (ORR) and overall survival (OS) were stratified by subtypes and according to chemotherapy received. Correlation of GATA6 with the subtypes using gene expression profiling, in situ hybridization (ISH) were explored. Results: Between December 2015-May 2019, 195 patients (95%) had enough tissue for RNA sequencing; 39 (20%) were classified as basal-like and 156 (80%) as classical. RECIST response data were available for 157 patients; 29 basal-like and 128 classical where the ORR was 10% vs. 33% respectively (p=0.02). In patients with basal-like tumours treated with modified FOLFIRINOX (mFFX) (n=22) the progression rate was 60% compared to 15% in classical PDAC (p= 0.0002). Median OS in the intention to treat population (n=195) was 9.3 months for classical vs. 5.9 months for basal-like PDAC (HR 0.47 95% CI 0.32-0.69, p=0.0001). GATA6 expression by RNAseq highly correlated with the classifier (p<0.001) and ISH predicted the subtypes with sensitivity of 89% and specificity of 83%. In a multivariable analysis, GATA6 expression was prognostic (p=0.02). In exploratory analyses, basal-like tumours, could be identified by keratin 5, were more hypoxic and enriched for a T cell inflamed gene expression signature. Conclusions :The basal-like subtype is chemoresistant and can be distinguished from classical PDAC by GATA6 expression.